hotspot -WSS

hotspot

author：comprehensive 2025-10-01 04:45:07 - browse：67688

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Adopting new red light myopia treatments may be short

explore

WSS

Top private equity targets in 2023: cardiology, clinical trials, lasers

CDC recommends rationing of RSV shot due to shortages

Why Novartis is going to walk from its acquisition of MorphoSys

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Physician subsidies by hospitals soar in wake of No Surprises Act

leisure time

hotspot

hotspot

Supreme Court strikes down use of affirmative action

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Malaria cases in Florida and Texas: Here’s what you need to know

Physician subsidies by hospitals soar in wake of No Surprises Act

The high cost of giving birth even with insurance

Telehealth options flood the market as retailers push virtual care

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Anesthesiologist group: stop taking Ozempic before surgery

First Opinion Podcast: How to protect health care in times of war

explore

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Devoted Health’s losses in Medicare Advantage persist

Emergency medicine has repudiated 'excited delirium.' Now what?

Padmanee Sharma of MD Anderson at center of lawsuit over credit

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Traditional Chinese medicine benefits explored in new JAMA study

focus

explore

focus

entertainment